BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.85 USD
+0.04 (4.29%)
Updated Jul 17, 2024 03:59 PM ET
After-Market: $0.86 +0.01 (1.06%) 5:16 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
BioLineRx Ltd. [BLRX]
Reports for Purchase
Showing records 181 - 200 ( 205 total )
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
1Q13 Highlights Movement Across the Portfolio
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Licenses An Oncologic and Decent Ciliac Disease Data
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.